文献速递免疫规划慢病防控与筛查卫生政策与健康促进

挪威老年人群接种COVID-19 mRNA疫苗后全因死亡率的短期安全性

Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway.
PubMed 文献 · Vaccine · 2022-11-07

这项全国性队列研究纳入2020年12月27日挪威疫苗接种开始时688,152名≥70岁人群,按接种日期和社会人口学及临床特征1:1匹配已接种与未接种者,比较首剂mRNA疫苗接种后21天内全因死亡率;匹配样本显示接种组死亡率较低(总体HR 0.28,95%CI 0.24-0.31),未发现接种后短期死亡率增加的证据。

要点

  • ≥70岁人群接种组21天内全因死亡风险低于未接种组(HR 0.28,95%CI 0.24-0.31)。
  • 按使用卫生服务类型和年龄组分层的分析结果与总体结果相似。
  • 研究未发现接种后短期死亡率增加的证据。

核心结论

  • 在按影响接种与死亡的社会人口学及临床特征匹配后,老年人群接种组未发现短期死亡率增加的证据,接种组死亡率反而较低。

研究设计与样本

  • 全国性队列研究,纳入2020年12月27日挪威疫苗接种开始时688,152名年龄≥70岁个体,数据来自挪威COVID-19应急准备登记库。
  • 已接种与未接种者按接种日期以1:1比例匹配,匹配依据为社会人口学与临床特征。
  • 主要结局为首剂COVID-19 mRNA疫苗接种后21天内全因死亡;采用Kaplan-Meier法估计生存函数,并用Cox比例风险回归估计死亡HR及95%CI,总体及按卫生服务使用情况(无、居家、短期和长期养老院)和年龄组分层分析。

主要发现

  • 2020年12月27日至2021年3月31日期间,420,771名老年人(61.1%)接种了COVID-19疫苗。
  • 基于匹配研究样本的Kaplan-Meier估计显示,接种组与未接种组全因死亡率绝对风险差异较小,接种组死亡率较低,总体HR 0.28(95%CI 0.24-0.31)。
  • 按卫生服务使用情况和年龄组分层的分析获得相似结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There have been concerns about COVID-19 vaccination safety among frail older individuals. We investigated the relationship between COVID-19 mRNA vaccination and mortality among individuals aged ≥ 70 years and whether mortality varies across four groups of health services used. METHODS: In this nationwide cohort study, we included 688,152 individuals aged ≥ 70 years at the start of the Norwegian vaccination campaign (December 27, 2020). We collected individual-level data from theNorwegian Emergency Preparedness Register for COVID-19. Vaccinated and unvaccinated individuals were matched (1:1 ratio) on the date of vaccination based on sociodemographic and clinical characteristics. The main outcome was all-cause mortality during 21 days after first dose of COVID-19 mRNA vaccination. Kaplan-Meier survival functions were estimated for the vaccinated and unvaccinated groups. We used Cox proportional-hazards regression to estimate hazard ratios (HRs) of death between vaccinated and unvaccinated individuals, with associated 95% confidence intervals (CIs), overall and by use of health services (none, home-based, short- and long-term nursing homes) and age group. RESULTS: Between December 27, 2020, and March 31, 2021, 420,771 older individuals (61.1%) were vaccinated against COVID-19. The Kaplan-Meier estimates based on the matched study sample showed a small absolute risk difference in all-cause mortality between vaccinated and unvaccinated individuals, with a lower mortality in the vaccinated group (overall HR 0.28 [95% CI: 0.24-0.31]). Similar results were obtained in analyses stratified by use of health services and age group. CONCLUSION: We found no evidence of increased short-term mortality among vaccinated individuals in the older population after matching on sociodemographic and clinical characteristics affecting vaccination and mortality.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lopez-Doriga Ruiz P, Gunnes N, Michael Gran J, et al. Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway. Vaccine. 2022. PMID: 36376216. doi:10.1016/j.vaccine.2022.10.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。